ClinicalTrials.gg
RecruitingNCT07938242Updated Nov 16, 2026

Comparison of Local Methylcobalamin and Subcutaneous Lidocaine in Subacute Herpetic Neuralgia

An interventional study of Methylcobalamin and Injection lidocaine in Subacute Herpetic Neuralgia, sponsored by CMH Multan Institute of Medical Sciences. Recruiting at 1 site in Pakistan. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by CMH Multan Institute of Medical Sciences · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Neuralgia with a site in Pakistan — 4 open to participants now, 6 under way, none of them phase 3. Neuralgia · Pakistan.

Planned enrollment
7th of 16
60 · median 60
Started
2026
with 5 others
No phase
14 of 16
4 open now
Registered
16th of 16
by date
Lead sponsor
1 of 16
CMH Multan Institute of Medical Sciences

Among the 16 studies in Neuralgia with a site in Pakistan, this one is the 7th largest by planned enrollment, is one of 6 that started in 2026, is one of 14 with no phase, and was the 16th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

4 of the 16 studies in Neuralgia with a site in Pakistan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Neuralgia with a site in Pakistan, or all of them as a file.
02

Study summary

This randomized controlled trial will compare methylcobalamin and lidocaine injections for pain relief in 60 patients with subacute herpetic neuralgia over four weeks.

Read the detailed description

This randomized controlled trial will compare the efficacy of local subcutaneous methylcobalamin injection versus subcutaneous lidocaine injection in patients aged 40-70 years with unilateral subacute herpetic neuralgia and baseline pain score greater than 6 on the visual analogue scale (VAS). A total of 60 patients will be randomly allocated to two groups, with 30 patients in each group. Group A will receive methylcobalamin injection (1 mg/2 mL), while Group B will receive lidocaine injection (1%, 2 mL), six times per week for four weeks. Pain intensity and sleep disturbance will be assessed at baseline and after 28 days of treatment. Treatment efficacy will be defined as a pain score below 3 at the end of treatment. Adverse effects will also be monitored and recorded. The study will be conducted at the Department of Dermatology, Combined Military Hospital (CMH), Multan, over six months following synopsis approval.

03

Conditions studied

  • Subacute Herpetic Neuralgia

Browse trials for

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

>Inclusion Criteria:

  • Patients aged 40-70 years, male or female.
  • Unilateral subacute herpetic neuralgia, defined as dermatomal neuropathic pain more than 30 days and up to 90 days after rash onset.
  • Baseline pain score greater than 6 on the Visual Analogue Scale (VAS).

Exclusion Criteria:

  • Diffuse neuropathic pain extending beyond the affected dermatome.
  • Cognitive impairment.
  • Use of topical agents or nerve-blocking agents within 10 days before enrolment.
  • patients receiving at a dose of 2 mg/kg/day for more than 14 days or undergoing chemotherapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Methylcobalamin Injection Group

    Participants will receive local subcutaneous methylcobalamin injection (1 mg/2 mL), six times per week for four weeks.

    Drug: Methylcobalamin

  • Active comparator
    Lidocaine Injection Group

    Participants will receive local subcutaneous lidocaine injection (1%, 2 mL), administered six times per week for four weeks.

    Drug: Injection lidocaine

Interventions

  • Methylcobalamin injection (1 mg/2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks.

  • DrugInjection lidocaine

    Lidocaine inLidocaine injection (1%, 2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks.

06

What researchers measure

Primary outcomes

  1. Pain score

    Change in pain intensity measured using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (maximum bearable pain). Treatment efficacy is defined as a pain score below 3 at 28 days after randomization.

    Time frame: Baseline (Day 1) and Day 28 (end of treatment).

Secondary outcomes

  1. Sleep Disturbance Score

    Sleep disturbance assessed using a numeric rating scale ranging from 0 (no disturbance) to 10 (severe disturbance).

    Time frame: Baseline (Day 1) and Day 28 (end of treatment).

  2. Adverse Effects

    Assessment and recording of adverse effects, including redness, swelling, hematoma formation, dizziness, and urticaria following injections.

    Time frame: Throughout the 4-week treatment period (Days 1-28). with observation for one hour after each injection session.

07

Study locations

1 of 1 sites recruiting
  • Cmh Multan
    Multan, Punjab Province 60000, Pakistan
    Recruiting
08

References and documents

Publications

  • Patil A, Goldust M, Wollina U. Herpes zoster: A Review of Clinical Manifestations and Management. Viruses. 2022 Jan 19;14(2):192. doi: 10.3390/v14020192. PubMed 35215786 ↗
  • Ramadhani A, Astuti I, Widiastuti MG, Purwanti N. Methylcobalamin as a candidate for chronic peripheral neuropathic pain therapy: review of molecular pharmacology actiona. Korean J Pain. 2024 Oct 1;37(4):299-309. doi: 10.3344/kjp.24171. PubMed 39344358 ↗
  • Xu G, Lv ZW, Feng Y, Tang WZ, Xu GX. A single-center randomized controlled trial of local methylcobalamin injection for subacute herpetic neuralgia. Pain Med. 2013 Jun;14(6):884-94. doi: 10.1111/pme.12081. Epub 2013 Apr 8. PubMed 23566267 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2027, 6 months after the start.

Of 246 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 6 months is below that.

Counting every sponsor, half of 264 studies reached it within 24 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 16, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938242
Lead sponsor
CMH Multan Institute of Medical Sciences
Responsible party
Hijab Fatima (Principal invsestigator, CMH Multan Institute of Medical Sciences) — Principal investigator
First posted
Nov 16, 2026
Start date
Sep 1, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mecobalamin

Start the discussion